胃肠道神经内分泌肿瘤(GE-NETs)是一组起源于消化道肽能神经元和神经内分泌细胞的恶性肿瘤,能产生多种肽类激素而引起特征性的内分泌综合征,但仅少数患者出现特异性的临床症状。治愈是治疗的首要目标,其次是控制症状及延缓肿瘤进展。手术是传统的一线治疗方案和唯一可达到治愈目的的有效方法。但是,多数患者因在初次诊断NETs时即已出现转移而失去手术根治机会。这部分患者需要接受长期的术后相关治疗,以达到缓解症状、抑制肿瘤生长转移、改善患者预后的目的。生长抑素类似物,如长效奥曲肽能缓解肿瘤所导致的临床症状并延缓其进展,且与生物靶向制剂如依维莫司联合应用对抑制肿瘤增殖具有协同作用。全身肽受体靶向放射治疗也是未来治疗NETs的新途径。 Gastrointestinal neuroendocrine tumors (GE-NETs) are a group of malignant tumors that originate in the peptic peptide neurons and neuroendocrine cells of the digestive tract. They produce various peptide hormones and cause characteristic endocrine syndromes. However, only a few patients Occurrence of specific clinical symptoms. Cure is the primary goal of treatment, followed by control of symptoms and delay of tumor progression. Surgery is the traditional first-line treatment and the only effective way to achieve the goal of cure. However, most patients lose the opportunity for radical surgery because they have already metastasized when they first diagnosed NETs. This part of patients need to receive long-term postoperative related treatment in order to achieve the purpose of relieving symptoms, inhibiting tumor growth and metastasis and improving the prognosis of patients. Somatostatin analogs, such as long-acting octreotide, can ameliorate the clinical symptoms caused by tumors and delay their progression, and synergistically inhibit the tumor proliferation in combination with bio-targeted agents such as everolimus. Targeted radiotherapy with systemic peptide receptors is also a new way to treat NETs in the future.